Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2020-01-30. The firm is focused on the discovery and development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. The Company’s lead product candidate, BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of epidermal growth factor receptor (EGFR) mutations, including allosteric and canonical mutations. Its second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic B-Raf Proto-Oncogene (BRAF) Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as rat sarcoma virus (RAS) mutations, which has the potential to avoid paradoxical activation.